Co-morbidity and functional deficits independently contribute to quality of life before chemotherapy in elderly cancer patients

Ulrich Wedding,Bernd Röhrig,Almuth Klippstein,Christina Brix,Ludger Pientka,Klaus Höffken
DOI: https://doi.org/10.1007/s00520-007-0228-9
IF: 3.1
2007-02-21
Supportive Care in Cancer
Abstract:Goal of the workThe quality of life (QoL) of patients with cancer is a major area of concern for both patients and their physicians. The independent contribution of functional impairment and co-morbidity to QoL is unclear.Materials and methodsWe investigated initial global QoL in 477 patients: 195 cancer patients aged 60 years or older (group A), 152 cancer patients below the age of 60 years (group B), admitted as inpatients for chemotherapy initiation and 130 patients aged 60 years or older admitted for non-cancer-related disorders (group C). Global QoL was assessed by the EORTC-QLQ-C30 subscale, functional status by the Karnofsky Performance Scale (KPS) and the Instrumental Activities of Daily Living (IADL) scale, and co-morbidity by the Cumulative Illness Rating Scale (CIRS).ResultsIn multivariate analyses, global QoL is significantly associated with KPS, IADL and co-morbidity in group A (r2 = 0.27), with KPS and IADL in group B (r2 = 0.23), and with age, KPS and IADL in group C (r2 = 0.38).ConclusionsIADL contributes to global QoL in addition to the known effect of KPS. In addition, co-morbidity independently influences global QoL in elderly cancer patients.
oncology,health care sciences & services,rehabilitation
What problem does this paper attempt to address?